Annovis Bio Inc (NYSE:ANVS) saw its stock drop 26.5% on Thursday after disclosing the pricing details for a dilutive equity offering.
The Phase 3 clinical-stage biotechnology firm announced an underwritten sale of 5,263,156 shares of common stock at a price of $1.90 per share. The offering includes accompanying warrants granting the holder the right to purchase up to 5,263,156 additional shares. Each warrant carries an exercise price of $2.50 per share and will become exercisable six months after issuance. The warrants will expire five years and six months from their issuance date.
The company said the shares and warrants will be issued separately but can only be bought together in the offering. Annovis expects to receive gross proceeds of approximately $10 million before accounting for underwriting discounts, commissions, and other offering expenses. That estimate does not include any potential proceeds that may arise later should holders exercise the warrants.
The offering is slated to close on or about April 10, 2026, subject to customary closing conditions. Canaccord Genuity is serving as the sole bookrunner for the transaction.
Annovis is advancing buntanetap, an experimental oral therapy being developed for neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease.
Context and immediate market reaction
The announced financing and its specific terms - notably the pairing of shares with long‑dated warrants and the exclusion of potential warrant exercise proceeds from the stated gross proceeds - coincided with a sharp intraday move lower in the company’s share price. The structure of the deal and its dilutive nature were identified by market participants as the proximate cause of the decline.
What the filing makes clear
- The offering consists of 5,263,156 common shares priced at $1.90 per share.
- Accompanying warrants to purchase the same number of shares carry a $2.50 exercise price, exercisable after six months and expiring five years and six months from issuance.
- Expected gross proceeds are about $10 million before underwriting and other expenses; future warrant exercises are not included in that figure.
The company’s filing also makes explicit that closing remains conditional on customary requirements, keeping the completion of the transaction subject to standard execution risks.